Your fact-checks will appear here
Drugs for cognitive or behavioral management of Alzheimer's symptoms
Short-term drug studies using fMRI-based measures—both cerebral blood flow (CBF) assessed with arterial spin labeling (ASL) or inferred from BOLD and functional connectivity (FC) from resting‑state fM...
Pregabalin and cholinesterase inhibitors produce distinct adverse-effect patterns in older adults: pregabalin primarily causes central nervous system effects (dizziness, somnolence) and has been assoc...
The FDA currently recognizes two classes of Alzheimer’s treatments: disease-targeted, anti-amyloid immunotherapies that have been shown to reduce brain amyloid and modestly slow cognitive decline in e...